pGEN-mSmo Citations (4)

Originally described in: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.
Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA Nature. 2000 Aug 31;406(6799):1005-9. PubMed Journal

---

Articles Citing pGEN-mSmo

Articles
A ligand-directed divergent catalytic approach to establish structural and functional scaffold diversity. Lee YC, Patil S, Golz C, Strohmann C, Ziegler S, Kumar K, Waldmann H. Nat Commun. 2017 Feb 14;8:14043. doi: 10.1038/ncomms14043. PubMed
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. Chahal KK, Li J, Kufareva I, Parle M, Durden DL, Wechsler-Reya RJ, Chen CC, Abagyan R. PLoS One. 2019 Sep 20;14(9):e0214901. doi: 10.1371/journal.pone.0214901. eCollection 2019. PubMed
Orphan receptor GPR37L1 remains unliganded. Ngo T, Wilkins BP, So SS, Keov P, Chahal KK, Finch AM, Coleman JLJ, Kufareva I, Smith NJ. Nat Chem Biol. 2021 Apr;17(4):383-386. doi: 10.1038/s41589-021-00748-z. Epub 2021 Mar 1. PubMed
TMED2 binding restricts SMO to the ER and Golgi compartments. Di Minin G, Holzner M, Grison A, Dumeau CE, Chan W, Monfort A, Jerome-Majewska LA, Roelink H, Wutz A. PLoS Biol. 2022 Mar 30;20(3):e3001596. doi: 10.1371/journal.pbio.3001596. eCollection 2022 Mar. PubMed

If you have published an article using this material, please email us at to have your article added to this page.